Clinical Scorecard: Assessment of Bone Marrow Alterations and Myelotoxic Chemotherapy through Longitudinal MR-based Proton-Density Fat Fraction (PDFF) and T2* Analysis

At a Glance

Key Highlights

• Myelotoxic chemotherapy leads to increased bone marrow fat fraction and decreased hematopoietic function, increasing risk of osteoporosis and fractures.
• MRI-based proton density fat fraction (PDFF) mapping provides a radiation-free, quantitative assessment of bone marrow fat composition.
• Combined PDFF and T2* MRI measurements can detect bone marrow changes longitudinally and may serve as non-invasive biomarkers for marrow damage and osteoporosis risk.

Guideline-Based Recommendations

Diagnosis

• Use MRI-based PDFF mapping to quantitatively assess vertebral bone marrow fat composition without radiation exposure.
• Exclude vertebrae with fractures or degenerative changes from analysis to ensure accurate marrow assessment.
• Consider longitudinal MRI assessments before and after myelotoxic chemotherapy to monitor marrow alterations.

Management

• Early detection of bone marrow conversion via MRI can guide timely induction of therapies to reduce osteoporosis and fracture risk.
• Implement bone anti-resorptive therapy in oncologic patients with increased marrow fat fraction to prevent fragility fractures.

Monitoring & Follow-up

• Perform MRI scans within 2 months before and at least 2 months after chemotherapy to evaluate marrow changes.
• Use PDFF and T2* measurements to monitor marrow composition changes over time in patients receiving myelotoxic chemotherapy.

Risks

• Myelotoxic chemotherapy-induced marrow fat increase correlates with reduced hematopoiesis and bone mineral density, elevating fracture risk.
• Radiation-based imaging modalities (DXA, quantitative CT) carry additional radiation exposure and costs.

Patient & Prescribing Data

Patients receiving myelotoxic chemotherapy regimens such as FOLFIRINOX, Sorafenib, Gemcitabine, and Gemcitabine + Cisplatin

MRI-based PDFF and T2* imaging can identify marrow toxicity and guide management to mitigate osteoporosis and fracture risk during chemotherapy.

Clinical Best Practices

• Match patients with controls by sex, age, chemotherapy duration, and MRI timing for comparative marrow assessment.
• Use chemical shift encoding-based water-fat separation MRI techniques at 3T with multi-echo gradient-echo sequences for PDFF and T2* quantification.
• Manually segment vertebral bodies excluding cortical bone and pathological vertebrae for accurate marrow fat and T2* measurement.
• Apply low flip angle (3°) MRI protocols to minimize T1 bias in fat quantification.

References

• Myelotoxic chemotherapy and bone marrow toxicity overview
• MRI-based PDFF for bone marrow fat assessment
• Correlation of BMFF and BMD in osteoporosis
• Water-fat MR imaging for marrow composition changes
• T2* measurements and bone mineral density correlation